Premium
Bioengineered corneal stroma: from laboratory to clinical adoption
Author(s) -
Rafat Mehrdad
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2019.8139
Subject(s) - medicine , corneal transplantation , cornea , keratoconus , transplantation , corneal transplant , surgery , ophthalmology
Blindness caused by corneal stromal disease and injuries affects millions worldwide, with the greatest burden in low‐ to middle‐income countries with inadequate donation and tissue banking infrastructure to meet the demand for sight‐restoring corneal transplantation. We bioengineered a regenerative cell‐free corneal scaffold from medical‐grade type I collagen and developed a minimally‐invasive implantation method avoiding the need for surgical suturing or long‐term immunosuppression. Applying good manufacturing practices and third‐party certified biocompatibility, toxicity, sterility and long‐term shelf life studies, sterile corneal scaffolds were tested in preclinical animal models and in a first clinical case series. Scaffolds integrated with recipient tissue and supported host cell ingrowth without inflammation or scarring. 22 subjects with advanced keratoconus were implanted with the bioengineered scaffold without complications. During 6–12 months of follow‐up, no rejection, inflammation, vascularization or adverse event occurred. Visual acuity, spherical refractive error, keratometry, corneal thickness and volume all improved significantly in the cohorts. Initially contact lens‐intolerant patients were tolerant postoperatively and are eligible for refractive surgery to optimize visual acuity. Results indicate bioengineered scaffold implantation can restore vision in patients with advanced stromal disease, avoiding more invasive procedures and the need for donor tissue.